According to the Xintiandi announcement, the company recently received a European Pharmacopeia certificate of applicability for moxifloxacin hydrochloride raw materials issued by the European Medicines Quality Administration. The certificate will take effect from September 18, 2026. Moxifloxacin hydrochloride is a quinolone antibiotic used to treat infectious diseases caused by sensitive pathogens. This certification shows that the European standard market recognizes the quality of this API. It indicates that the API can be sold in the European market and other regulated markets that recognize the CEP certificate, which has a positive impact on the company's diversification of products and expansion of the international market. The international API business is uncertain due to overseas market conditions, exchange rate fluctuations, etc. Investors are kindly requested to pay attention to investment risks.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.